Large-Scale AAV Manufacturing: The Road from Concept to Ready-to-Use Platform
The success of Adeno Associate Vector (AAV)-based gene therapies rely on production platforms that can ensure high quality, large scale and cost-effective manufacturing. In the context of clinical studies or commercial phase, an important manufacturing challenge is the availability of an efficient and scalable AAV production process.
To address this goal AGC Biologics is developing two production platforms for large scale production of AAVs. The first platform is adherent-based using the leading fixed-bed disposable bioreactor iCELLis® for clinical and commercial manufacturing. The second platform is suspension-based to meet higher scale-up demands and take full advantage of an animal-free culture system to improve safety, performance and consistency.
In this webinar, we focus on critical parameters for scalable production during both upstream and downstream process development, with a focus on achieving scalable transfection in both adherent and suspension platforms. We further discuss the flexibility that these new platforms will offer, in terms of AAV serotypes and Gene of Interest and their availability as ready-to-use platforms for large scale production of 200L and beyond.
To address this goal AGC Biologics is developing two production platforms for large scale production of AAVs. The first platform is adherent-based using the leading fixed-bed disposable bioreactor iCELLis® for clinical and commercial manufacturing. The second platform is suspension-based to meet higher scale-up demands and take full advantage of an animal-free culture system to improve safety, performance and consistency.
In this webinar, we focus on critical parameters for scalable production during both upstream and downstream process development, with a focus on achieving scalable transfection in both adherent and suspension platforms. We further discuss the flexibility that these new platforms will offer, in terms of AAV serotypes and Gene of Interest and their availability as ready-to-use platforms for large scale production of 200L and beyond.
